Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer

Borghaei Hossein; Gettinger Scott; Vokes Everett E.; Chow Laura Q. M.; Burgio Marco Angelo; Carpeno Javier de Castro; Pluzanski Adam; Arrieta Oscar; Frontera Osvaldo Aren; Chiari Rita; Butts Charles; Wojcik-Tomaszewska Joanna; Coudert Bruno; Garassino Marina Chiara; Ready Neal; Felip Enriqueta; Garcia Miriam Alonso; Waterhouse David; Domine Manuel; Barlesi Fabrice; Antonia Scott; Wohlleber Markus; Gerber David E.; Czyzewicz Grzegorz; Spigel David R.; Crino Lucio; Eberhardt Wilfried Enst Erich; Li Ang; Marimuthu Sathiya; Brahmer Julie

首页> 外文期刊>Journal of Clinical Oncology >Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer

【24h】

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer

机译：来自随机，第III期试验的五年成果Checkmate 017和057：Nivolumab与先前治疗的非小细胞肺癌中的多西紫杉醇

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

PURPOSE Immunotherapy has revolutionized the treatment of advanced non-small-cell lung cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab showed an improvement in overall survival (OS) and favorable safety versus docetaxel in patients with previously treated, advanced squamous and nonsquamous NSCLC, respectively. We report 5-year pooled efficacy and safety from these trials.

机译：目的免疫治疗已经彻底改变了晚期非小细胞肺癌（NSCLC）的治疗方法。在两项III期试验（CheckMate 017和CheckMate 057）中，与多西他赛相比，nivolumab分别在先前治疗的晚期鳞状和非鳞状非小细胞肺癌患者中显示出总体生存率（OS）的改善和良好的安全性。我们报告了这些试验的5年综合疗效和安全性。

著录项

来源
《Journal of Clinical Oncology》 |2021年第7期|共26页
作者
Borghaei Hossein; Gettinger Scott; Vokes Everett E.; Chow Laura Q. M.; Burgio Marco Angelo; Carpeno Javier de Castro; Pluzanski Adam; Arrieta Oscar; Frontera Osvaldo Aren; Chiari Rita; Butts Charles; Wojcik-Tomaszewska Joanna; Coudert Bruno; Garassino Marina Chiara; Ready Neal; Felip Enriqueta; Garcia Miriam Alonso; Waterhouse David; Domine Manuel; Barlesi Fabrice; Antonia Scott; Wohlleber Markus; Gerber David E.; Czyzewicz Grzegorz; Spigel David R.; Crino Lucio; Eberhardt Wilfried Enst Erich; Li Ang; Marimuthu Sathiya; Brahmer Julie;
展开▼
作者单位

Fox Chase Canc Ctr 333 Cottman Ave Philadelphia PA 19111 USA;

Yale Comprehens Canc Ctr New Haven CT USA;

Univ Chicago Med &

Biol Sci Div Chicago IL 60637 USA;

Univ Washington Seattle Canc Care Alliance Seattle WA 98195 USA;

Ist Sci Romagnolo Studio &

Cura Tumori IRST IRCCS Meldola Italy;

Hosp Madrid Madrid Spain;

Maria Sklodowska Curie Inst Oncol Warsaw Poland;

Inst Nacl Cancerol Mexico City DF Mexico;

Ctr Invest Clin Bradford Hill Santiago Chile;

Osped S Maria Misericordia Perugia Italy;

Cross Canc Inst Edmonton AB Canada;

Prov Ctr Oncol Gdansk Gdansk Poland;

Ctr Georges Francois Leclerc Dijon France;

Inst Nazl Studio &

La Cura Milan Italy;

Duke Univ Med Ctr Durham NC USA;

Vall dHebron Univ Hosp Barcelona Spain;

Hosp Univ Virgen Del Rocio Seville Spain;

Oncol Hematol Care Inc Cincinnati OH USA;

Fdn Jimenez Diaz IIS FJD Madrid Madrid Spain;

Aix Marseille Univ AP HM CNRS INSERM CRCM Marseille France;

H Lee Moffitt Canc Ctr &

Res Inst Tampa FL USA;

Robert Bosch Canc Ctr Gerlingen Germany;

UT Southwestern Med Ctr Dallas TX USA;

John Paul 2 Hosp Krakow Poland;

Sarah Cannon Res Inst Tennessee Oncol PLLC Nashville TN USA;

Ist Sci Romagnolo Studio &

Cura Tumori IRST IRCCS Meldola Italy;

Univ Med Essen Essen Germany;

Bristol Myers Squibb Princeton NJ USA;

Bristol Myers Squibb Princeton NJ USA;

Johns Hopkins Kimmel Canc Ctr Baltimore MD USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Nab-paclitaxel (abraxane)-based chemotherapy to treat elderly patients with advanced non-small-cell lung cancer: a single center, randomized and open-label clinical trial [J] . Hanrui Chen, Xuewu Huang, Shutang Wang, 中国癌症研究（英文版） . 2015,第002期
2. Phase I trial of dose escalation of capecitabine combined with fixed docetaxel in previously treated patients with non-small cell lung cancer [J] . Qjang Lin, Yue＇e Liu, Chuilin Chang, 中德临床肿瘤学杂志：英文版 . 2012,第001期
3. Study protocol of the Asian XELIRIrnProjecT (AXEPT): a multinational, randomized,rnnon‑inferiority, phase III trial of second‑linernchemotherapy for metastatic colorectal cancer,rncomparing the efficacy and safety of XELIRIrnwith or without bevacizumab versus FOLFIRIrnwith or without bevacizumab [J] . Masahito Kotaka, Hiroshi Matsumoto, Kentaro Yamazaki, 癌症（英文版） . 2016,第012期
4. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057) [J] . Horn Leora, Spigel David R., Vokes Everett E., Journal of Clinical Oncology . 2017,第35期

机译：Nivolumab对先前治疗的非小细胞肺癌患者的多西紫杉醇：两年随机，开放标签，第III期试验的两年成果（Checkmate 017和Checkmate 057）
5. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate O17 and O57: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer (vol 39, pg 723, 2021) [J] . Borghaei Journal of Clinical Oncology . 2021,第10期

机译：来自随机，III期试验的五年成果检查o17和O57：Nivolumab与先前治疗的非小细胞肺癌的多西紫杉醇（Vol 39，PG 723,2021）
6. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases [J] . Vokes E. E., Ready N., Felip E., Annals of oncology: official journal of the European Society for Medical Oncology . 2018,第4期

机译：Nivolumab与先前治疗的晚期非小细胞肺癌（Checkmate 017和Checkmate 057）的Docetaxel）：肝转移患者的3年更新和结果
7. PHOSPHOPROTEOMICS OF NON-SMALL-CELL LUNG CANCER CELLS TREATED WITH ERLOTINIB REVEALS DRUG-RESISTANT SIGNATURES AND POTENTIAL TARGETS [C] . Jun Adachi, Yuichi Abe, Maiko Nagano, International Mass Spectrometry Conference . 2018

机译：用厄洛替尼处理的非小细胞肺癌细胞的磷脂蛋白酶揭示了耐药象征和潜在目标
8. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
9. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized Open-Label Phase III Trials (CheckMate 017 and CheckMate 057) [O] . Leora Horn, David R. Spigel, Everett E. Vokes, -1

机译：在接受过治疗的晚期非小细胞肺癌患者中Nivolumab与多西他赛的比较：两项随机开放标签III期试验（CheckMate 017和CheckMate 057）的两年结果
10. OA14.04 Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC [O] . S. Gettinger, H. Borghaei, J. Brahmer, 2019

机译：OA14.04从随机，第3阶段试验中的五年成果Checkmate 017/057：Nivolumab与先前处理的NSCLC中的Docetaxel
11. Prospective, Randomized Trial of Intravenous Hydroxocobalamin Versus Whole Blood Transfusion Compared to No Treatment for Class III Hemorrhagic Shock Resuscitation in a Prehospital Swine Model. [R] . Bebarta, V. S., Garrett, N., Boudreau, S., 2015

机译：静脉注射羟钴胺素与全血输注的前瞻性随机试验相比，在院前猪模型中未治疗III类失血性休克复苏。

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer

摘要

著录项

相似文献

相关主题

期刊订阅